Hanchor-KY (7827) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 漢康-KY創

Hanchor-KY (7827) reported revenue of NT$0 for Oct 2026. Revenue for Jan–Oct 2026 was NT$27.7 million (-91.1% year on year).

In Oct 2026, it ranked No. 156 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Sep 2025 NT$312.2 million25/09Apr 2026 NT$9.5 million26/04Jul 2026 NT$18.1 million26/07

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$0——
Sep 2026NT$0-100.0%—
Aug 2026NT$0—-100.0%
Jul 2026NT$18.1 million——
Jun 2026NT$0——
May 2026NT$0—-100.0%
Apr 2026NT$9.5 million——
Mar 2026NT$0——
Feb 2026NT$0——
Jan 2026NT$0——
Dec 2025NT$0——
Nov 2025NT$0——
Oct 2025NT$0—-100.0%
Sep 2025NT$312.2 million——
Aug 2025NT$0——
Jul 2025NT$0——
Jun 2025NT$0——
May 2025NT$0——
Apr 2025NT$0——
Mar 2025NT$0——
Feb 2025NT$0——
Jan 2025NT$0——
Dec 2024NT$0——
Nov 2024NT$0——
Oct 2024NT$0——

Jan–Oct 2026 cumulative: NT$27.7 million (-91.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Hanchor-KY vs PEC / Hanchor-KY vs Lotus Pharm / Hanchor-KY vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

增減變動差異原因: 係本年為臨床藥品銷貨收入,去年同期則為授權相關履約義務已經達成而認列相關授權收入

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16